<DOC>
	<DOCNO>NCT01034917</DOCNO>
	<brief_summary>This 48 week randomize , prospective , control , open-label , proof-of-concept pilot clinical trial . Patients HIV-1 infection HAART PI-based regimen randomize switch PI etravirine ( 400 mg dissolve water every 24 hour ) continue approach . The aim study compare virological efficacy etravirine-based regimen standard PI-containing regimen .</brief_summary>
	<brief_title>Switching From Protease Inhibitor ( PI ) Etravirine HIV-1 Infected Subjects With Viremia Suppression</brief_title>
	<detailed_description>Etravirine second generation non-nucleoside analogue reverse transcriptase inhibitor ( NNRTI ) approve U.S. Food Drug Administration ( FDA ) January 2008 European Medicines Agency September 2008 clinical use adult incomplete virologic suppression resistance previous NNRTI antiretroviral class . A question explore whether subject sustain undetectable HIV-1 RNA-levels experience antiretroviral-related toxicity safely switch current PI etravirine . This treatment strategy could allow improvement tolerability lipid profile would permit easy posology ( 400 mg dissolve water every 24 hour ) . We design proof-of-concept study test efficacy safety switch Protease Inhibitor ( PI ) etravirine subject viral suppression antiretroviral strategy simplification therapy , base high antiviral potency , low toxicity , together easy posology ( water dissolution ) . Patients HIV-1 infection HAART PI-based regimen randomize switch PI etravirine ( 400 mg dissolve water every 24 hour ) continue approach . The primary endpoint would percentage patient maintain virological suppression week 48 .</detailed_description>
	<mesh_term>Viremia</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<criteria>1 . Adult patient diagnosis HIV1 infection . 2 . Antiretroviral therapy start least 12 month , always HAART combination include 2 NRTIs plus PI . 3 . Maintained undetectable plasma HIV1 RNA ( VL &lt; 50 copies/mL ) since begin antiretroviral therapy , least 6 month . 4 . Absence suspect documented resistance mutation RT associate NNRTIs NRTI . 5 . Patient least one follow condition : Dyslipemia ( LDL cholesterol &gt; 130 mg/dL triglyceride &gt; 350 mg/dL ) derive current PI regimen current use lipidlowering agent due dyslipemia , Antiretroviralrelated gastrointestinal disturbance , Low patient 's satisfaction associate current regimen posology ( BID regimen , ritonavir use , ritonavir intoleranceâ€¦ ) . 6 . Good treatment adherence . 7 . Voluntary write informed consent . 1 . Previous therapy mono dual antiretroviral therapy initial HAART era . 2 . Previous antiretroviral treatment failure , treatment interruption ( A ) blip ( B ) viral load ( VL &gt; 50 copies/mL ) . 3 . Acute infection uncontrolled chronic infection 2 month previous inclusion . 4 . Pregnancy fertile woman willing pregnant . 5 . Clinically significant malabsorption syndrome within 30 day prior randomization . ( A ) Patients past make interruption treatment ( provide last year ) may consider candidate study , meet criterion inclusion , since break treatment assume emergence mutation . ( B ) Small blip precede forward 2 undetectable viral load take care .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Active Comparator</keyword>
	<keyword>Placebo Comparator</keyword>
	<keyword>Sham Comparator</keyword>
	<keyword>No intervention</keyword>
	<keyword>Other</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>